Financhill
Back

Dyne Therapeutics Quote, Financials, Valuation and Earnings

Dyne Therapeutics Price Quote

$30.06
-0.16 (-0.53%)
(Updated: October 30, 2024 at 2:30 PM ET)

Dyne Therapeutics Key Stats

Sell
35
Dyne Therapeutics (DYN) is a Sell

Day range:
$29.94 - $30.67
52-week range:
$6.66 - $47.45
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.91%

Volume:
581.4K
Avg. volume:
1M
1-year change:
356.5%
Market cap:
$3B
Revenue:
$0
EPS:
$-3.59

How Much Does Dyne Therapeutics Make?

Data Unavailable

Is Dyne Therapeutics Growing As A Company?

Data Unavailable

Dyne Therapeutics Stock Price Performance

  • Did Dyne Therapeutics Stock Go Up Last Month?
    Dyne Therapeutics share price went down by -10.67% last month
  • Did DYN's Share Price Rise Over The Last Year?
    DYN share price rose by 356.5% over the past 1 year

What Is Dyne Therapeutics 52-Week High & Low?

Dyne Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Dyne Therapeutics?

  • How Much Debt Does Dyne Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Dyne Therapeutics Have?
    Cash and short term investments quarterly total is $778.8M
  • What Is Dyne Therapeutics’s Book Value Per Share?
    Book value per share is 7.74

Is Dyne Therapeutics Cash Flow Positive?

  • What Is DYN Cash Flow From Operations?
    Cash flow from operations (TTM) is -$219M
  • What Is Dyne Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $788.9M
  • What Is Dyne Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$129.6M

Dyne Therapeutics Return On Invested Capital

Data Unavailable

Dyne Therapeutics Earnings Date & Stock Price

Dyne Therapeutics Competitors

  • Who Are Dyne Therapeutics's Competitors?
    Below is a list of companies who compete with Dyne Therapeutics or are related in some way:
    • Capricor Therapeutics Inc (CAPR)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Regenxbio Inc (RGNX)
    • Sarepta Therapeutics Inc (SRPT)
    • Vertex Pharmaceuticals Inc (VRTX)

Dyne Therapeutics Dividend Yield

Dyne Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.71%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 52.20
Upside from Last Price: 72.73%

Major Shareholders

  • How many DYN shares are owned by institutional investors?
    140.9M DYN shares are owned by institutional investors
  • How many DYN shares are owned by insiders?
    2M DYN shares are owned by insiders